Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.38 |
| ▸ | SOD3 | P08294 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254587 | 0.98 | GNAO1 (0.40) | GNAO1GNAI3GNAI1SOD3ALOX5 | |
| SCHEMBL3253791 | 0.94 | MEN1 (0.35) | GNAO1GNAI3GNAI1SOD3MEN1 | |
| SCHEMBL3044885 | 0.86 | — | — | |
| SCHEMBL6961881 | 0.78 | KEAP1 (0.32) | — | |
| SCHEMBL447925 | 0.77 | — | — | |
| SCHEMBL11969012 | 0.74 | OPRD1 (0.30) | — | |
| SCHEMBL361683 | 0.74 | — | — | |
| SCHEMBL1476931 | 0.73 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL1081166 | 0.69 | ALDH1A1 (0.36) | GNAO1GNAI3GNAI1ALOX5MEN1 | |
| SCHEMBL11599897 | 0.69 | POLB (0.52) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280978-B1 | PYRROLIDINE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-04-24 | — | — | EP | claimed |
| EP-1204649-B1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-10-17 | — | — | EP | claimed |
| EP-1671969-A2 | Thiazolyl inhibitors of tec family tyrosine kinases | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | claimed |
| CN-1671699-A | Photochromic bis-naphthopyran compounds and methods for their manufacture | JOHNSON & JOHNSON VISION CARE (US) | 2005-09-21 | — | — | CN | claimed |
| CN-1617861-A | Photochromic oxazine compounds and methods for their manufacture | JOHNSON & JOHNSON VISION CARE (US) | 2005-05-18 | — | — | CN | claimed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050004120-A1 | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | PHARMACIA ITALIS S.P.A. (IT) | 2005-01-06 | — | — | US | claimed |
| US-6784198-B1 | 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-31 | — | — | US | claimed |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-06-10 | — | — | US | claimed |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-04-08 | — | — | US | claimed |
| EP-1347971-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | claimed |
| CN-1425009-A | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-06-18 | — | — | CN | claimed |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | claimed |
| WO-2002050071-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-27 | — | — | WO | claimed |
| EP-1204649-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-15 | — | — | EP | claimed |
| WO-2001014353-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA, S.P.A. (IT) | 2001-03-01 | — | — | WO | claimed |
| US-6114365-A | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-09-05 | — | — | US | claimed |
| US-5292741-A | Macrocycles incorporating quinazolinones | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | claimed |
| EP-0096299-B1 | HYDROXYIMINO AND ALKOXYIMINO DERIVATIVES OF 1,4-DIHYDROPYRIDINE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREFROM | Pierrel S.p.A. (IT) | 1989-02-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | GNAO1 2737/4885GNAI3 2113/4885GNAI1 1425/4885 |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | GNAO1 2786/4885GNAI3 1052/4885GNAI1 834/4885 |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | GNAO1 2786/4885GNAI3 1052/4885GNAI1 834/4885 |
| US-20050004120-A1 | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | CCAR2, BCL2, ROS1 | GNAO1 2094/4885GNAI3 1343/4885GNAI1 1201/4885 |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | GNAO1 2786/4885GNAI3 1052/4885GNAI1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.